Abstract:Despite significant progress in clinical management, drug resistance remains a major obstacle. Recent research based on protein degradation to restrain drug resistance has attracted wide attention, and several therapeutic strategies such as inhibition of proteasome with bortezomib and proteolysis-targeting chimeric have been developed. Compared with intervention at the transcriptional level, targeting the degradation process seems to be a more rapid and direct strategy. Proteasomal proteolysis and lysosomal proteolysis are the most critical quality control systems responsible for the degradation of proteins or organelles. Although proteasomal and lysosomal inhibitors (e.g., bortezomib and chloroquine) have achieved certain improvements in some clinical application scenarios, their routine application in practice is still a long way off, which is due to the lack of precise targeting capabilities and inevitable side effects. In-depth studies on the regulatory mechanism of critical protein degradation regulators, including E3 ubiquitin ligases, deubiquitylating enzymes (DUBs), and chaperones, are expected to provide precise clues for developing targeting strategies and reducing side effects. Here, we discuss the underlying mechanisms of protein degradation in regulating drug efflux, drug metabolism, DNA repair, drug target alteration, downstream bypass signaling, sustaining of stemness, and tumor microenvironment remodeling to delineate the functional roles of protein degradation in drug resistance. We also highlight specific E3 ligases, DUBs, and chaperones, discussing possible strategies modulating protein degradation to target cancer drug resistance. A systematic summary of the molecular basis by which protein degradation regulates tumor drug resistance will help facilitate the development of appropriate clinical strategies.

Deubiquitinating Enzymes: Promising Targets for Drug Resistance.

The role of deubiquitinating enzymes in cancer drug resistance

The Roles of Deubiquitinating Enzymes in Cancer Therapy

Roles and Mechanisms of Deubiquitinases (dubs) in Breast Cancer Progression and Targeted Drug Discovery

Deubiquitylating Enzymes in Cancer and Immunity

Targeting DNA repair pathways: a novel approach to reduce cancer therapeutic resistance.

Recent advances in the development of deubiquitinases inhibitors as antitumor agents

Emerging Role of DUBs in Tumor Metastasis and Apoptosis: Therapeutic Implication

Deubiquitinating enzymes: potential regulators of the tumor microenvironment and implications for immune evasion

Protein degradation: expanding the toolbox to restrain cancer drug resistance

Deubiquitinases in Ovarian Cancer: Role in Drug Resistance and Tumor Aggressiveness

Deubiquitinases in cancer

The Emerging Role of Deubiquitinating Enzymes in Genomic Integrity, Diseases, and Therapeutics.

Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches

Deubiquitinating Enzyme: A Potential Secondary Checkpoint of Cancer Immunity.

DUBbing Cancer: Deubiquitylating Enzymes Involved in Epigenetics, DNA Damage and the Cell Cycle As Therapeutic Targets

Dysregulation of deubiquitination in breast cancer

Advances in deubiquitinating enzymes in lung adenocarcinoma

A review of deubiquitinases and thier roles in tumorigenesis and development

Drug resistance mechanisms and treatment strategies mediated by Ubiquitin-Specific Proteases (USPs) in cancers: new directions and therapeutic options

Uncovering the deubiquitinase activity landscape of breast cancer.